Over the years, we have built strong relationships with many different companies across the drug development and contract manufacturing industry that have allowed us to become one of the leading API pharma companies.
From raw material suppliers, to specialist analytical service providers and distribution companies, our network helps us to deliver smooth processes, remain flexible and expand our offering.
Two collaborations we are particularly proud of, Catalent Services and Reach Separations, have allowed us to deliver more rounded chemistry services and become one of the leading pharmaceutical manufacturers.
Catalent Services: the pharma development specialists
In 2012, we formed a strategic alliance with our friends down at Catalent Services in Nottingham. The partnership was devised to enable the two contract research organisations and pharmaceutical manufacturers to deliver end-to-end services from initial drug discovery through to early and late phase manufacturing.
Complementing our expertise in custom synthesis, chemical process development, solid state chemistry and manufacturing, Catalent Services specialises in advanced characterisation of pharmaceutical and biological materials, formulation & analytical development and manufacturing.
In just six months, we completed our first API manufacturing and formulation collaborative project, helping a pharmaceutical client faced with a very tight deadline to successfully fill two patent applications.
Reach Separations: a purification specialist
We also have close ties with purification specialist Reach Separations. Based at BioCity in Nottingham, this alliance allows us to deliver more specialist purification and separation services to assist our early stage development and medicinal chemistry services.
As part of the collaboration, we provide custom separation for companies in drug discovery. This includes chiral, reverse phase and normal phase chromatography using supercritical fluid chromatography (SFC) and high performance liquid chromatography (HPLC).
Reach Separations’ technical group is led by purification specialist and Technical Director Phil Abbott who has worked in the pharmaceutical industry for almost 20 years, including several years at AstraZeneca as a separation science group leader.
Expanding our services further
In addition to our external relationships with other companies, our internal growth means that we are now more productive than ever. In 2011, we proudly became part of the IPCA family, which has given us seven additional API sites across India, giving us the ability to work at a commercial scale and much more.
In 2018, we also acquired Pisgah, which further expanded our capabilities with pilot plant facilities. We now work on a wide range of APIs.
In 2019, we will also be securing a commercial API manufacturing license at our facility in the North East of England, which will further expand our capabilities.
If you have a project in mind, or you would like to discuss how our collaborations could help your compound, then get in touch today.